OB Holdings Bhd
MMYX:OBHB0.21
MYR
+0.00
(-2.33%)
OB Holdings Bhd
MYX:OBHB
(Bursa Malaysia)
Recent
price
0.21
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
MYR
•
in mil. unless spec.Working Capital
MYR
•
in mil. unless spec.Growth Rates
MYR
•
in mil. unless spec.Quarterly Revenue
MYR
•
in mil. unless spec.Quarterly Earnings Per Share
MYR
•
in mil. unless spec.Quarterly Dividends Per Share
MYR
•
in mil. unless spec.- Similar Companies
- Business
- OB Holdings Berhad is a Malaysia-based investment holding company engaged in the provision of end-to-end manufacturing services for fortified food and beverages and dietary supplements to third-party brand owners. The company manufactures, sells, and markets its house brands, including Bonlife, GoHerb, Kids Vite, Sleepin' Beauté, Zen Night, EZ:Nitez, Beyoute, Zen Youte, and Zenliv; offers contract packing services for milk powder, tea leaves, honey, herb powder, fruit powder, and liquid chlorophyll into retail packaging sizes; and engages in trading milk powder, laboratory test services, freight services, and ad hoc sales of packaging materials, pallets, and face masks. Through its subsidiaries Orient Biotech Sdn. Bhd., Orient Laboratories Sdn. Bhd., and Bonlife Sdn. Bhd., it provides product development, research, formulation consultation, raw material sourcing, and regulatory documentation support. Founded in 1995 and headquartered in Batu Caves, Selangor, the company operates primarily in Malaysia with distribution reaching Hong Kong, Thailand, Singapore, China, Australia, and Taiwan, targeting retailers, e-commerce platforms, and third-party brands in the health and wellness sector. In recent developments, OB Holdings completed its initial public offering on the ACE Market of Bursa Malaysia in October 2024, raising RM28.8 million to fund factory expansion, machinery purchases, product development, marketing, and working capital. The company commenced construction of a new factory in Serendah, Selangor, in January 2024, expected to be completed in the first half of 2025 with commercial production starting in the first half of 2026 to more than double production capacity. In May 2025, its subsidiary Orient Biotech entered into letters of intent with CSPC Innovation Pharmaceutical Co., Ltd. and CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., subsidiaries of CSPC Pharmaceutical Group Limited, to collaborate on co-developing advanced functional raw ingredients for fortified foods, beverages, and supplements. Additionally, in early 2025, it partnered with CTG Group to launch a Youth Entrepreneurship Programme aimed at nurturing young talent.